Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
Last trade$12.65
Day change-$0.175 (-1.37%)
Day range$12.10 – $12.89
Volume300,737
Market cap$796M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$795.75M
Price / earnings
76.17×
Price / book
2.14×
Price / sales
1.57×
EV / sales
1.55×
EV / EBITDA
15.83×
Profitability
Earnings per share
$0.17
Return on assets
1.61%
Return on equity
2.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.18×
Current ratio
1.76×
Quick ratio
1.76×
Cash ratio
0.51×
Cash flow
Price / cash flow
8.71×
Price / free cash flow
9.85×
Free cash flow
$80.75M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PHR, quarterly periods
Line item
Q2 FY2027 Jul 31, 2026
Q1 FY2027 Apr 30, 2026
Q4 FY2026 Jan 31, 2026
Q3 FY2026 Oct 31, 2025
Q2 FY2026 Jul 31, 2025
Q1 FY2026 Apr 30, 2025
Q4 FY2025 Jan 31, 2025
Q3 FY2025 Oct 31, 2024
Revenue
$129.46M
$130.94M
$127.07M
$120.33M
$117.26M
$115.94M
$109.68M
$106.8M
Cost of revenue
$19.27M
$17.66M
$18.99M
$18.34M
$17.4M
$16.64M
$16.51M
$17.85M
Gross profit
$110.19M
$113.28M
$108.08M
$102M
$99.86M
$99.3M
$93.17M
$88.95M
Selling, general and administrative
$41.1M
$42.57M
$51.62M
$41.64M
$44.44M
$42.45M
$47.28M
$49.7M
Research and development
$27.57M
$28.33M
$30.93M
$29.45M
$29.27M
$31.83M
$29.63M
$29.32M
Total operating expenses
$102.58M
$106.53M
$113.63M
$98.26M
$101.36M
$102.59M
$100.79M
$102.79M
Operating income
$7.61M
$6.75M
-$5.56M
$3.74M
-$1.51M
-$3.29M
-$7.61M
-$13.84M
Interest expense
-$1.73M
-$2.3M
-$6.95M
$0
-$391K
-$435K
-$2.35M
$0
Income before taxes
$3.24M
$4.72M
-$10.32M
$5.13M
-$563K
-$3.18M
-$5.38M
-$13.96M
Income taxes
$1.32M
$1.76M
-$11.62M
$854K
-$1.22M
$735K
$1.01M
$442K
Net income
$1.92M
$2.96M
$1.3M
$4.27M
$654K
-$3.91M
-$6.39M
-$14.4M
Net income attributable to common shareholders
$1.92M
$2.96M
$1.3M
$4.27M
$654K
-$3.91M
-$6.39M
-$14.4M
EBITDA
$17.6M
$16.7M
$4.24M
$11.33M
$5.9M
$3.59M
-$680K
-$5.43M
Basic earnings per share
$0.03
$0.05
$0.02
$0.07
$0.01
-$0.07
-$0.11
-$0.25
Diluted earnings per share
$0.03
$0.05
$0.02
$0.07
$0.01
-$0.07
-$0.11
-$0.25
Recent news
Company coverage with links to the original publishers.
Dare Bioscience reported a Q3 loss of $0.18 per share, missing the consensus estimate of $0.13 loss by 38.46%. The company posted revenues of $0.05 million, missing estimates by 99.19%. DARE shares have declined 65.9% year-to-date versus the S&P 500's 10.5% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
MDxHealth SA reported a quarterly loss of $0.16 per share, significantly worse than the consensus estimate of $0.07, and missed revenue expectations by 20.31% with $22.71 million in revenues. The stock has declined 95.9% year-to-date and received a Zacks Rank #3 (Hold) rating. The company has consistently underperformed consensus estimates over the last four quarters.
Phreesia stock fell 6.58% after Raymond James analyst John Ransom downgraded the company from outperform to market perform. The downgrade was triggered by concerns over declining organic revenue growth that could turn negative in H2, combined with worries about AI spending pressuring EBITDA and potential budget constraints among healthcare provider customers. Despite 10% YoY revenue growth and nearly tripled profitability in Q2, the company missed earnings expectations.
Phreesia (PHR) stock fell 6.33% after reporting Q2 fiscal 2027 earnings that missed analyst expectations on net income despite beating revenue estimates. While the company posted strong net income growth to $1.9 million ($0.03 per share) and 10% revenue growth to $129.5 million, analysts expected $0.09 per share in earnings. The company maintained full-year guidance and highlighted new products AccessOne and ProviderConnect, but the analyst recommends holding off on investment given the modest performance and ongoing restructuring.
Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.